↓ Skip to main content

An assessment of the strategy and status of COVID-19 vaccination in India

Overview of attention for article published in Immunologic Research, April 2023
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter
25 X users

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
An assessment of the strategy and status of COVID-19 vaccination in India
Published in
Immunologic Research, April 2023
DOI 10.1007/s12026-023-09373-5
Pubmed ID
Authors

Sneh Lata Gupta, Surbhi Goswami, Ananya Anand, Namrata Naman, Priya Kumari, Priyanka Sharma, Rishi K. Jaiswal

Abstract

The COVID-19 disease continues to cause devastation for almost 3 years of its identification. India is one of the leading countries to set clinical trials, production, and administration of COVID-19 vaccination. Recent COVID-19 vaccine tracker record suggests that 12 vaccines are approved in India, including protein subunit, RNA/DNA, non-replicating viral vector, and inactivated vaccine. Along with that 16 more vaccines are undergoing clinical trials to counter COVID-19. The availability of different vaccines gives alternate and broad perspectives to fight against viral immune resistance and, thus, viruses escaping the immune system by mutations. Using the recently published literature on the Indian vaccine and clinical trial sites, we have reviewed the development, clinical evaluation, and registration of vaccines trial used in India against COVID-19. Moreover, we have also summarized the status of all approved vaccines in India, their associated registered clinical trials, manufacturing, efficacy, and their related safety and immunogenicity profile.

X Demographics

X Demographics

The data shown below were collected from the profiles of 25 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 13 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 3 23%
Researcher 2 15%
Professor 1 8%
Student > Doctoral Student 1 8%
Student > Bachelor 1 8%
Other 1 8%
Unknown 4 31%
Readers by discipline Count As %
Nursing and Health Professions 4 31%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Chemical Engineering 1 8%
Chemistry 1 8%
Medicine and Dentistry 1 8%
Other 0 0%
Unknown 5 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 May 2023.
All research outputs
#2,430,211
of 25,863,888 outputs
Outputs from Immunologic Research
#67
of 953 outputs
Outputs of similar age
#47,313
of 425,255 outputs
Outputs of similar age from Immunologic Research
#3
of 17 outputs
Altmetric has tracked 25,863,888 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 953 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 425,255 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.